4.

Analysis of Kaplan-Meier's survival for miR-222 serum expression variable (fold regulation) in advanced stage NSCLC with positive EGFR gene mutation. A: EGFR positive (Log-rank test, P=0.049, 95). Median survival: High (equal or more higher than median): 74 d; Low (less than median): 293 d; 1 year survival rate: High (equal or more higher than median): 28.6%; Low (less than median): 100.0%. B: EGFR negative (Log-rank test, P=0.962). Median survival: High (equal or more higher than median): 92 d; Low (less than median): 68 d; 1 year survival rate: High (equal or more higher than median): 50.0%; Low (less than median): 35.7%.